晚期糖基化終末產(chǎn)物(AGE)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法,高敏型)
High Sensitive ELISA Kit for Advanced Glycation End Product (AGE)
AGEs; Advanced Glycation End Products
- 編號(hào)HEB353Ge
- 物種Pan-species (General，通用)相同的名稱，不同的物種。
- 實(shí)驗(yàn)方法競(jìng)爭(zhēng)抑制
- 反應(yīng)時(shí)長(zhǎng)3h
- 檢測(cè)范圍19.75-1,600ng/mL
- 靈敏度最小可檢測(cè)劑量小于等于7.13ng/mL.
- 樣本類型serum, plasma and other biological fluids
- 下載英文說明書 中文說明書
- 規(guī)格48T96T96T*596T*1096T*100
- 價(jià)格¥ 3284¥ 4692¥ 21114¥ 39882¥ 328440
- 欲了解實(shí)際交易價(jià)格和更多情況，請(qǐng)與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
產(chǎn)品包裝(模擬)
產(chǎn)品包裝(模擬)
實(shí)驗(yàn)結(jié)果圖
標(biāo)準(zhǔn)曲線圖
通過ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
特異性
本試劑盒用于檢測(cè)晚期糖基化終末產(chǎn)物(AGE)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法,高敏型)，經(jīng)檢測(cè)與其它相似物質(zhì)無明顯交叉反應(yīng)。
由于受到技術(shù)及樣本來源的限制，不可能完成對(duì)所有相關(guān)或相似物質(zhì)交叉反應(yīng)檢測(cè)，因此本試劑盒有可能與未經(jīng)檢測(cè)的其它物質(zhì)有交叉反應(yīng)。
回收率
分別于定值血清及血漿樣本中加入一定量的晚期糖基化終末產(chǎn)物(AGE)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法,高敏型)（加標(biāo)樣品），重復(fù)測(cè)定并計(jì)算其均值，回收率為測(cè)定值與理論值的比率。
| 樣本 | 回收率范圍(%) | 平均回收率(%) |
| serum(n=5) | 79-99 | 95 |
| EDTA plasma(n=5) | 86-93 | 90 |
| heparin plasma(n=5) | 85-101 | 94 |
精密度
精密度用樣品測(cè)定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內(nèi)差：取同批次試劑盒對(duì)低、中、高值定值樣本進(jìn)行定量檢測(cè),每份樣本連續(xù)測(cè)定20 次，分別計(jì)算不同濃度樣本的平均值及SD值。
批間差：選取3個(gè)不同批次的試劑盒分別對(duì)低、中、高值定值樣本進(jìn)行定量測(cè)定，每個(gè)樣本使用同一試劑盒重復(fù)測(cè)定8次，分別計(jì)算不同濃度樣本的平均值及SD值。
批內(nèi)差： CV<10%
批間差： CV<12%
線性
在定值血清及血漿樣本內(nèi)加入適量的晚期糖基化終末產(chǎn)物(AGE)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法,高敏型)，并倍比稀釋成1:2，1:4，1:8，1:16的待測(cè)樣本，線性范圍即為稀釋后樣本中晚期糖基化終末產(chǎn)物(AGE)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法,高敏型)含量的測(cè)定值與理論值的比率。
| 樣本 | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 80-99% | 96-105% | 94-102% | 93-105% |
| EDTA plasma(n=5) | 78-101% | 84-101% | 99-105% | 90-102% |
| heparin plasma(n=5) | 98-105% | 78-89% | 82-89% | 79-95% |
穩(wěn)定性
經(jīng)測(cè)定，試劑盒在有效期內(nèi)按推薦溫度保存，其活性降低率小于5%。
為減小外部因素對(duì)試劑盒破壞前后檢測(cè)值的影響，實(shí)驗(yàn)室的環(huán)境條件需盡量保持一致，尤其是實(shí)驗(yàn)室內(nèi)溫度、濕度及溫育條件。其次由同一實(shí)驗(yàn)員來進(jìn)行操作可減少人為誤差。
實(shí)驗(yàn)流程
1. 實(shí)驗(yàn)前標(biāo)準(zhǔn)品、試劑及樣本的準(zhǔn)備；
2. 加樣（標(biāo)準(zhǔn)品及樣本）50µL，
加入50µL檢測(cè)液A(臨用前配制);
37°C溫育1小時(shí)。
3. 洗板3次；
4. 加檢測(cè)溶液B100µL，37°C孵育30分鐘；
5. 洗板5次；
6. 加TMB底物90µL，37°C孵育10-20分鐘；
7. 加終止液50µL，立即450nm讀數(shù)。
實(shí)驗(yàn)原理
本試劑盒應(yīng)用競(jìng)爭(zhēng)抑制酶聯(lián)免疫分析法測(cè)定標(biāo)本中待測(cè)物質(zhì)水平。將晚期糖基化終末產(chǎn)物(AGE)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法,高敏型)單克隆抗體包被微孔板，制成固相載體，往包被抗體的微孔中同時(shí)加入生物素標(biāo)記的抗原和待測(cè)抗原(標(biāo)準(zhǔn)品或樣本)，待測(cè)抗原與生物素標(biāo)記抗原對(duì)特異性抗體進(jìn)行競(jìng)爭(zhēng)結(jié)合。溫育后經(jīng)洗滌去掉未結(jié)合物，然后加入HRP標(biāo)記的親和素，經(jīng)過溫育和徹底洗滌后加入底物TMB顯色。TMB在過氧化物酶的催化下轉(zhuǎn)化成藍(lán)色，并在酸的作用下轉(zhuǎn)化成最終的黃色。待測(cè)標(biāo)本濃度越高，標(biāo)記抗原和抗體的結(jié)合就越受到抑制，顯色愈淺。顯色的深淺與酶量呈正相關(guān)，而與樣品中待測(cè)物質(zhì)含量呈負(fù)相關(guān)。用酶標(biāo)儀在450nm波長(zhǎng)下測(cè)定吸光度（O.D.值），計(jì)算樣品濃度。
贈(zèng)品
相關(guān)產(chǎn)品
| 編號(hào) | 適用物種：Pan-species (General，通用) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| NPB353Ge01 | 晚期糖基化終末產(chǎn)物(AGE)天然蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| APB353Ge01 | 晚期糖基化終末產(chǎn)物(AGE)活性蛋白 | Cell?culture;?Activity?Assays. |
| PAB353Ge01 | 晚期糖基化終末產(chǎn)物(AGE)多克隆抗體 | WB; IHC; ICC; IP. |
| LAB353Ge71 | 晚期糖基化終末產(chǎn)物(AGE)多克隆抗體(生物素標(biāo)記) | WB; IHC; ICC. |
| LAB353Ge81 | 晚期糖基化終末產(chǎn)物(AGE)多克隆抗體(異硫氰酸熒光素標(biāo)記) | IHC; ICC;ELISA |
| MAB353Ge21 | 晚期糖基化終末產(chǎn)物(AGE)單克隆抗體 | WB; IHC; ICC; IP. |
| HEB353Ge | 晚期糖基化終末產(chǎn)物(AGE)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法,高敏型) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| CEB353Ge | 晚期糖基化終末產(chǎn)物(AGE)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| LMB353Ge | 晚期糖基化終末產(chǎn)物(AGE)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
| KSB353Ge11 | 晚期糖基化終末產(chǎn)物(AGE)檢測(cè)試劑盒DIY材料(酶聯(lián)免疫吸附試驗(yàn)法) | Main materials for "Do It (ELISA Kit) Yourself". |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| Human Immunology | Threshold serum concentrations of tumour necrosis factor alpha (TNFα) as a potential marker of the presence of microangiopathy in children and adolescents with type 1 diabetes mellitus (T1DM)[PubMed: S0198885912005642] |
| Experimental Dermatology | A long-standing hyperglycaemic condition impairs skin barrier by accelerating skin ageing process[PubMed: 22017743] |
| J Hum Nutr Diet. | Daily intake of vitamin D- or calcium-vitamin D-fortified Persian yogurt drink (doogh) attenuates diabetes-induced oxidative stress: evidence for antioxidative properties of vitamin D.[Pubmed: 23829785] |
| Gene | Association of RAGE gene polymorphism with circulating AGEs level and paraoxonase activity in relation to macro-vascular complications in Indian type 2 diabetes mellitus patients.[Pubmed: 23721855] |
| Gynecol Endocrinol. | Lipoprotein-associated phospholipase A2 and AGEs are associated with cardiovascular risk factors in women with history of gestational diabetes mellitus.[Pubmed:24397392] |
| Microvasc Res. | Role of advanced glycation end product (AGE)-induced receptor (RAGE) expression in diabetic vascular complications[Pubmed:24984291] |
| Free Radic Res. | Nitroxides prevent protein glycoxidation in vitro.[Pubmed:25363554] |
| Sleep and Breathing | Serum advanced glycation end products are associated with insulin resistance in male nondiabetic patients with obstructive sleep apnea[Pubmed:25566941] |
| Chem Biol Interact | Ascorbic acid and protein glycation[PubMed: 26163454] |
| Osteoarthritis Cartilage | Establishment of a rabbit model to study the influence of advanced glycation end products accumulation on osteoarthritis and the protective effect of pioglitazone[PubMed: 26321377] |
| journal of human hypertension | Relationship between serum levels of endogenous secretory RAGE and blood pressure in male nondiabetic patients with obstructive sleep apnea[PubMed: 25994997] |
| Redox Biol. | Glycation of bovine serum albumin by ascorbate[PubMed: 26202868] |
| J Oral Pathol Med | Impact of morbid obesity and bariatric surgery on antioxidant/oxidant balance of the unstimulated and stimulated human saliva[PubMed: 26608886] |
| J Agric Food Chem | Inhibition of Advanced Glycation Endproduct Formation by Lotus Seedpod Oligomeric Procyanidins through RAGE-MAPK Signaling and NF-κB Activation in High-Fat-Diet Rats.[PubMed: 26207852] |
| Kineziologija | ADVANCED GLYCATION END PRODUCTS'RESPONSE TO RESISTANCE TRAINING IN POSTMENOPAUSAL WOMEN WITH TYPE II DIABETES[140251: ] |
| Food Funct. | Effects of edible bird's nest on hippocampal and cortical neurodegeneration in ovariectomized rats[PubMed: 25920003] |
| Molecular and Cellular Endocrinology | Beneficial effects of urine-derived stem cells on fibrosis and apoptosis of myocardial, glomerular and bladder cells[Pubmed:26952874] |
| Advances in Experimental Medicine and Biology | Effects of S-Nitroso-N-Acetyl-Penicillamine (SNAP) on Inflammation, Lung Tissue Apoptosis and iNOS Activity in a Rabbit Model of Acute Lung Injury[Pubmed:27334732] |
| Eur J Vasc Endovasc Surg | The Receptor for Advanced Glycation End Products (Rage) and Its Ligands in Plasma and InfrainCavia (Guinea pig )inal Bypass Vein[Pubmed:26905625] |
| molecular and cellular endocrinology | Berberine exerts renoprotective effects by regulating the AGEs-RAGE signaling pathway in mesangial cells during diabetic nephropathy.[pubmed:28087385] |
| cellular physiology and biochemistry | Inhibition of Methylglyoxal-Induced AGEs/RAGE Expression Contributes to Dermal Protection by N-Acetyl-L-Cysteine.[pubmed:28214842] |
| General?Physiology?and?Biophysics | Glutathione?is the?main?endogenous?inhibitor?of?protein?glycation.[pubmed:28218612] |
| Osteoarthritis?and?Cartilage | Establishment?of a?rabbit?model?to?study?the?influence?of?advanced?glycation?end?productsaccumulation?on?osteoarthritis?and the?protective?effect?of pioglitazone.[pubmed:26321377] |
| Scientific Reports | Advanced glycation end products promote VEGF expression and thus choroidal neovascularization via Cyr61-PI3K/AKT signaling pathway[pubmed:29097668] |
| INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE | Lychee seed extract protects against neuronal injury and improves cognitive function in rats with type II diabetes mellitus with cognitive impairment[pubmed:29138799] |
| 臺(tái)灣農(nóng)業(yè)研究 | (臺(tái)灣農(nóng)業(yè)研究67 (4): 355-364) 香菇柄水萃物改善糖尿病降低阿茲海默氏癥罹病風(fēng)險(xiǎn)初探[] |
| Biological?Trace?Element?Research | Altered Mineral Metabolism and Disequilibrium Between Calcification Promoters and Inhibitors in Chronic Hemodialysis Patients[Pubmed: 30847765] |
| International journal of molecular sciences | Cellular Metabolomics Reveal the Mechanism Underlying the Anti-Atherosclerotic Effects of Aspirin Eugenol Ester on Vascular Endothelial Dysfunction[Pubmed: 31261711] |
| Evidence-Based Complementary and Alternative Medicine | Fushiming Capsule Attenuates Diabetic Rat Retina Damage via Antioxidation and Anti-Inflammation[] |
| Journal of Alzheimers Disease | Effect of Advanced Glycation End Products on the Progression of Alzheimer's Disease[Pubmed: 31561370] |
| Life Sciences | Protective effect of vanillin on diabetic nephropathy by decreasing advanced glycation end products in rats[Pubmed: 31759039] |
| Journal of Diabetes Research | Supplementation with Korean Red Ginseng Improves Current Perception Threshold in Korean Type 2 Diabetes Patients: A Randomized, Double-Blind, Placebo …[Pubmed: 32025522] |
| Pharmaceuticals | A New Insight into Meloxicam: Assessment of Antioxidant and Anti-Glycating Activity in In Vitro Studies[Pubmed: 32927809] |
| Mol Cell Endocrinol | Advanced glycation end products enhance macrophage polarization to the M1 phenotype via the HIF-1α/PDK4 pathway[Pubmed: 32464167] |
| archives of gerontology and geriatrics | The effect of Korean Red Ginseng on sarcopenia biomarkers in type 2 diabetes patients[Pubmed: 32470863] |
| The Role of PPARγ in Hyperglycemia-induced Deleterious Effect on Chondrocytes[] | |
| Biomolecules | Young and Undamaged rMSA Improves the Healthspan and Lifespan of Mice[34439857] |
| Dietary Advanced Glycation End Products Shift the Gut Microbiota Composition and Induce Insulin Resistance in Mice[Pubmed:35210793] |
